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Abstract As emphasized in Part 1 of these guidelines, the
diagnosis of pulmonary embolism (PE) is confirmed or
refuted using ventilation/perfusion scintigraphy (V/PSCAN) or
multidetector computed tomography of the pulmonary arteries
(MDCT). To reduce the costs, the risks associated with false-
negative and false-positive diagnoses, and unnecessary radia-
tion exposure, preimaging assessment of clinical probability is
recommended. Diagnostic accuracy is approximately equal for
MDCT and planar V/PSCAN and better for tomography (V/
PSPECT). V/PSPECT is feasible in about 99% of patients, while
MDCT is often contraindicated. As MDCT is more readily
available, access to both techniques is vital for the diagnosis of
PE. V/PSPECT gives an effective radiation dose of 1.2–2 mSv.
For V/PSPECT, the effective dose is about 35–40% and the
absorbed dose to the female breast 4% of the dose fromMDCT
performed with a dose-saving protocol. V/PSPECT is recom-
mended as a first-line procedure in patients with suspected PE.
It is particularly favoured in young patients, especially
females, during pregnancy, and for follow-up and research.
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Abbreviations
COPD Chronic obstructive pulmonary disease
MAA Macroaggregated human albumin
MDCT Multidetector computed tomography of the
pulmonary arteries
PA Contrast-enhanced pulmonary angiography
PE Pulmonary embolism
V/PPLANAR Ventilation/perfusion scintigraphy with pla-
nar imaging
V/PSCAN Ventilation/perfusion scintigraphy
V/PSPECT Ventilation/perfusion single photon emission
computed tomography
Introduction and background
The primary objective of the Task Group was to develop
guidelines for the use of ventilation/perfusion scintigraphy
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for the diagnosis and follow up of PE. In the first part of the
Guidelines, the principles, techniques and interpretation with
a focus on V/PSPECT were presented with respect to the
diagnosis of PE and other diseases such as COPD, left heart
failure and pneumonia [1]. The objectives of this second part
were to define the importance of clinical probability together
with objective imaging tests and to analyse the advantages
and disadvantages of V/PSPECT compared to MDCT.
Referral criteria and assessment of clinical probability
Diagnosis of PE
Knowledge of predisposing factors is a useful guide to the
diagnosis, but as many as 26% to 47% of patients with a
first diagnosis of venous thromboembolism have no
recognizable risk factors for this disease [2]. The electro-
cardiograph may provide pointers to the presence of right
ventricular overload such as S1, Q3, T3, right bundle
branch block, right axis deviation and, in longstanding
cases, P-pulmonale. The chest radiograph may provide
evidence of atelectasis, raised hemidiaphragm, cardiome-
galy, pulmonary infarction and Westmark’s sign (vascular
rarefaction) [3]. However, while these are pointers, they are
not diagnostic of PE [4]. The chest radiograph is useful for
alternative diagnoses such as pneumothorax, pneumonia,
COPD, lung cancer or pulmonary fibrosis. Patients with PE
may have arterial hypoxaemia and hypocapnia [4–6].
However, these signs are nonspecific and are also seen in
patients without PE.
Assessment of the clinical probability of PE
The results of broad prospective studies lend support to the
concept that clinical probability assessment is an important
step in the diagnosis of PE [4, 7–11]. When considered
individually, symptoms, signs, or common laboratory tests
have limited diagnostic power. Jointly, however, they may
provide accurate assessment of the clinical probability of
PE.
Assessment of the clinical probability can be accom-
plished empirically or by means of a prediction rule. The
latter is preferable over empirical assessment, especially for
less experienced clinicians. In recent years, structured
prediction models for PE have been developed with the
very purpose of improving and easing the diagnostic
approach [12–18].
The Canadian model introduced by Wells at al. [17] is
the most frequently used prediction rule for suspected PE
(Table 1). It includes seven variables of which three refer to
well-recognized risk factors for PE. The model heavily
depends on the subjective judgement as to whether an
alternative diagnosis is less likely than PE and, as such, it
can hardly be standardized. The Wells’ model seems better
suited to rule out rather than to rule in the diagnosis of PE
[1, 14], and its performance is likely to be better in clinical
settings where the prevalence of the disease is expected to
be low [19].
Recently, a more precise prediction model [1, 15] was
introduced which rests on 16 variables including older age,
risk factors, preexisting cardiopulmonary diseases, relevant
clinical symptoms and signs, and the interpretation of the
electrocardiogram (Table 2). The area under the receiver
operating characteristic curve was 0.90 in the derivation
sample (n=1,100), and 0.88 in the validation sample
(n=400). In contrast to other prediction rules, the model
includes variables that are negatively associated with PE.
This gives the model greater flexibility, which may explain
why it performs equally well in detecting and in ruling out
PE. Also, instead of using a point-scale score proportional
to the regression coefficients, typical of other approaches
[13, 17, 18], the probability of PE is estimated directly from
the algebraic sum of the regression coefficients. This allows
prediction of the clinical probability as a continuous
function. It estimates likelihood ratios for PE precisely. Its
clinical value has been explored in a recent study [15]. To
facilitate the applicability of the model in clinical settings,
easy-to-use software is available for online computation of
the clinical probability on a palm computer and mobile
phone (http://www.ifc.cnr.it/pisamodel).
Combining clinical probability with objective testing for PE
Assessing the clinical probability of PE helps clinicians
choose the most appropriate objective test for diagnosing or
excluding PE (Fig. 1).
The measurement of D-dimer (a breakdown product of
crosslinked fibrin clot) is widely used in the investigative
work-up of patients with suspected venous thromboembo-
lism [20]. Quantitative assay of D-dimer, based on a rapid
ELISA method, has a high sensitivity (in the region of
95%) for venous thromboembolism [20]. Yet the test
features a low specificity (40%) because D-dimer may be
Table 1 Wells’ model
Predictor Score
Prior PE or venous thromboembolism 1.5
Heart rate >100 beats per minute 1.5
Recent surgery or immobilization 1.5
Signs of venous thromboembolism 3.0
Alternative diagnosis less likely than PE 3.0
Haemoptysis 1.0
Cancer 1.0
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raised in a number of conditions other than venous
thromboembolism such as acute myocardial infarction,
stroke, inflammation, active cancer, and pregnancy. The
specificity falls with age and, in the elderly, may reach only
10% [20]. Accordingly, a negative quantitative D-dimer test
has a high negative predictive value for venous thrombo-
embolism. Results of outcome studies reveal that the risk of
developing PE in patients with low clinical probability, who
are untreated after a negative D-dimer test is <1% at
3 months after the initial evaluation [19, 20]. On the other
hand, due to the low predictive value, a positive quantita-
tive D-dimer test does not modify the pretest (clinical)
probability and is, therefore, clinically useless. Recent
evidence, however, suggests that very high D-dimer levels
are associated with a fourfold increase in the likelihood of
PE [21]. It may be important in assessing the burden of
thromboembolic disease [22] and may have prognostic
significance [23, 24].
Clinical algorithm for investigation of patients
with suspected PE
Stable patients
Based on the above, if the clinical likelihood of PE is low
and the quantitative D-dimer is negative, a diagnosis of PE
is unlikely and further investigations are not required
(Fig. 1). If the clinical likelihood of PE is low and the
quantitative D-dimer is positive, further investigations for a
range of diagnoses including PE may be required, partic-
ularly if the D-dimer level is markedly elevated. If the
clinical probability is other than low, it seems more
appropriate to skip the D-dimer test and refer the patient
directly to the appropriate imaging technique (Fig. 1). This
may be V/PSCAN or MDCT depending on the local
availability, medical expertise, and the patient’s clinical
condition. V/PSCAN has virtually no contraindications and
yields a substantially lower radiation burden than MDCT.
The latter is more widely and readily available.
Haemodynamically unstable PE
If the patient presents with severe hypotension or cardio-
genic shock (Fig. 2), transthoracic echocardiography may
stand as the first-line imaging technique. It allows detection
of right heart dilatation and hypokinesis [25]. In rare
circumstances, it may visualize emboli within the right
heart cavities or main pulmonary artery [26]. Perfusion lung
scintigraphy is an alternative option as it may quickly show
multiple segmental or lobar perfusion defects that are
typical of acute PE [8]. If an acute dissection of the
thoracic aorta is suspected because of chest pain, MDCT
may offer the opportunity to evaluate for this differential
Clinical probability of PE
Low
Other than low
Quantitative D-dimer
Negative Positive
Lung scintigraphy Multidetector MDCT
No PE Further testing
Fig. 1 Diagnostic strategy
in stable patients according to
clinical probability of PE
Table 2 Clinical prediction model for PE (simplified Pisamodel)
Predictor Coefficient
Age 57–67 years 0.80
Age 68–74 years 0.87
Age 75–95 years 1.14
Male sex 0.60
Prior cardiovascular disease −0.51
Prior pulmonary disease −0.89
History of venous thromboembolism 0.64
Immobilization (>3 days) 0.42
Sudden onset dyspnoea 2.00
Orthopnoea −1.51
Chest pain 1.01
Haemoptysis 0.93
Fainting or syncope 0.66
Unilateral leg swelling suggestive of venous
thromboembolism
0.80
Fever >38°C −1.47
Wheezes −1.20
Crackles −0.61
ECG signs of acute cor pulmonale 1.96
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diagnosis. Given the need for haste in diagnosis and
treatment of such patients, the diagnostic strategy employed
at a particular institution must be adapted to the specific
clinical situation and to the local circumstances.
When the initial examination suggests massive PE
further action must be adapted to the clinical situation.
Thrombolytic therapy might be given. If not already
performed, a perfusion scan should be performed as soon
as possible as a basis for further follow-up.
Imaging studies in PE
As clarified in Part 1 [1], the diagnosis of PE relies upon
imaging tests, notably V/PSCAN and MDCT. These tech-
niques are discussed below with focus on the following:
Accuracy for PE diagnosis
Clinical feasibility with respect to contraindications
and availability
Radiation exposure
Suitability for follow up and research
Overall diagnostic strategies for good clinical practice
Diagnostic accuracy
MDCT is often recommended as the imaging test of first
choice for the diagnosis of PE [27]. The evidence base for the
use of MDCT as the principal imaging tool for the diagnosis
of PE is not as robust as was generally thought. There is an
emerging evidence base showing improved diagnostic accu-
racy for PE using V/PSPECT. The following is a discussion of
the merits of V/PSPECT versus MDCT in the diagnosis of PE.
In many clinical studies, including recent ones, compar-
isons between V/PSCAN and MDCT have been based upon
obsolete scintigraphic techniques and interpretation criteria
[7, 10]. In particular, PIOPED I found that 65% of
scintigraphy studies were nondiagnostic. It has been shown
that a reduction in the proportion of nondiagnostic studies
to 10% can be achieved even with V/PPLANAR with
adequate acquisition [28] and a holistic interpretation
strategy [28, 29]. With V/PSPECT and nonprobabilistic
interpretation, this proportion is further reduced to below
3% [30–34]. Applying PISAPED criteria to material from
PIOPED II the rate of nondiagnostic studies was 0% [35].
The lack of a satisfactory gold standard for the diagnosis of
PE poses difficulties for the assessment of sensitivity, specific-
ity and accuracy of all diagnostic methods for PE. The best
available benchmark is an adequate follow-up of the patients
for recurrence of PE or alternative diagnoses. Themost rigorous
study of MDCT in the diagnosis of PE is the PIOPED II study
which used 4–16-slice MDCT [10]. This study showed a
sensitivity for PE of 83% excluding nondiagnostic studies.
This led to the observation that “The false negative rate of
17% for MDCT indicates the need for additional information
to rule out PE” [36]. If nondiagnostic studies were included,
the overall sensitivity fell to 78%. In the PIOPED II study the
positive predictive value for a PE within a lobar pulmonary
artery was 97% but fell to 68% and 25% in segmental and
subsegmental pulmonary vessels, respectively.
After a negative single-slice CT study, PE occurred in
1.4% of patients in a meta-analysis of 4,637 patients [37].
After a negative PA study this was 1.6% [38], and after a
negative MDCT study 1.5% (n=318). After a negative V/
PSCAN, the occurrence of PE during follow-up was 0.4% in
a total of 1,877 patients [30, 39–41]. Freeman stated that
the results of the PIOPED II study “do not clearly support the
superiority of CT angiography over ventilation/perfusion
scanning for the diagnosis of PE” [42]. Notably, this
conclusion was based upon V/PPLANAR and probabilistic
interpretation. A direct comparison between V/PSPECT and
four-slice MDCT showed a higher sensitivity by V/PSPECT
[34]. In a recent retrospective study, Bajc et al. showed that
V/PSPECT had higher sensitivity, and specificity and fewer
nondiagnostic studies than 16-slice CT [30]. Further pro-
spective comparisons between up to date V/PSPECT and
Severe hypotension or shock
Echocardiography
Perfusion scintigraphy
MDCT
Right ventricular strain
Other findings
Suggestive of PE
Not suggestive of PE
Pulmonary vascular occlusion
Other findings
Fig. 2 Diagnostic strategy in
patients with severe hypotension
or shock
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MDCT are needed. In reading of V/PSPECT studies, low
interobserver variability has been shown by a kappa value of
0.92 [31].
In Part 1 of these guidelines additional diagnoses found on
V/PSPECT include COPD, left heart failure and pneumonia
[30]. MDCT provides valuable information about diagnoses
other than PE, such as aortic aneurysm, tumour, pleural
effusion and pneumonia.
Feasibility
PIOPED II illustrates well the limited clinical utility of
MDCT. In 50% of eligible patients, MDCT could not be
performed because of kidney failure, critical illness, recent
myocardial infarction, ventilator support and allergy to the
contrast agent. Furthermore, 6% of performed MDCT
studies were of insufficient quality for conclusive interpre-
tation. In about 1% complications including allergy,
contrast agent extravasation and increased creatinine level
were observed. By contrast, V/PSPECT has no contra-
indications and was performed in 99% of patients referred
in the study by Bajc et al. [30]. Complications do not occur,
and the rate of technically suboptimal studies is close to
zero. It is possible to accommodate patients who are
mechanically ventilated by connecting a nebulizer to the
inspiratory ventilator line. In rare cases, when V/PSPECT
cannot be performed, V/PPLANAR remains an alternative.
Availability
MDCT is available in nearly all medical centres and
community hospitals. Service is often available around the
clock seven days a week. V/PSPECT is available in many
fewer hospitals and seldom on a 24-hour basis. For this
reason the choice between MDCT and scintigraphy is often
determined by availability. In hospitals with nuclear
medicine facilities the choice of imaging may depend on
when scintigraphy is available.
Radiation dose
Image quality can be enhanced by allowing higher radiation
doses when using X-ray techniques and in isotope studies.
Obviously, any clinical routine should be based upon
procedures offering a radiation dose as low as possible
but with image quality that is proven appropriate with
respect to a particular diagnosis.
V/PSPECT
Radiation doses for V/PSPECT can be quite closely estimated
according to the International Commission for Radiation
Protection (ICRP). A systematic analysis of imaging
protocols for V/PSPECT has shown that 25–30 MBq of
99mTc-aerosol for ventilation and 100–120 MBq of 99mTc-
MAA for perfusion in combination with proper collimation
and time for imaging renders optimal V/PSPECT images for
the diagnosis of PE [43]. The protocol has documented
efficacy for the diagnosis of PE and also for left heart
failure [30, 44]. Using these activities the effective radiation
dose from V/PSPECT is 1.2–2 mSv (Table 1 in Part 1) [1].
The absorbed dose to the female breast is estimated as
0.8 mGy [45, 46]. During the first trimester, the data of
Hurwitz et al. applied to the recommended dose for
perfusion study (50 MBq) gives a fetal absorbed dose of
0.1–0.2 mGy [47].
MDCT
At centres with identical multislice scanners, the estimation
of absorbed doses may vary by a factor of 7 depending on
the CT protocol and other variables [48]. In general,MDCT
results in higher direct radiation and scatter doses than
single-slice CT [49–51]. This may change with the
introduction of radiation-saving protocols (see below). In
the literature, estimations of radiation dose from MDCT
vary within wide limits. According to ICRP [52], the
average effective dose for 4–16-detector MDCT is 5.4 mSv.
Notably, this information was based on computed rather
than measured dose data. Hurwitz et al. reported for a
current adult PE protocol with 64-detector MDCT a
measured effective dose of 19.9±1.38 mSv [53]. These
authors point out that the actual measured dose is about
50% higher than the computed dose. The absorbed dose to
the breasts was 35–42 mGy. Absorbed radiation dose to the
breast for a single-slice CT study was 20–50 mGy and 30–
50% greater with a four-slice CT [54].
In a very recent study, Hurwitz et al. [55] studied radiation
dose-saving protocols. Phantoms of women were exposed
to MDCT protocols with automatic current modulation,
lower tube voltage and bismuth shields over the chest. For
the medium sized woman with automatic current modula-
tion, the breast doses at 140 kVp were 62 mGy and 33 mGy
when bismuth shields were added. At 120 kVp the doses
were 44 mGy without shields and 20 mGy with shields.
Some limitations of the study were discussed. No phantom
with significant subcutaneous fat was studied. The authors
were not able to directly assess the effect of increased noise for
the diagnosis of PE. Dose-saving protocols are promising.
The fetal radiation dose from a 16-slice MDCT study
was recently analysed by Hurwitz et al. [47]. During the
first trimester the absorbed fetal dose was estimated as 0.24–
0.66 mGy and significantly higher later during gestation.
Recent studies have shown that MDCT is often technically
suboptimal during pregnancy. The rate of nondiagnostic
MDCT studies was 27.5% during pregnancy, versus 7.5% in
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nonpregnant women [56]. In 10 out of 16 pregnant women,
contrast opacification within the pulmonary arteries was
borderline or insufficient for diagnosis [57]. A reason for
poor diagnostic outcome of MDCT in pregnancy is
probably increased cardiac output and plasma volume.
V/PSPECT and MDCT
Based upon data from ICRP reports, the effective dose for
V/PSPECT with the recommended protocol is about 35–40%
of the dose from MDCT [45, 46, 52]. The dose to the
female breast for V/PSPECT is only 4% of the dose from
MDCTwith full dose-saving means according to Hurwitz et
al. [55]. This may have particular importance in pregnant
women with proliferating breast tissue [58]. During the first
trimester of pregnancy the fetal dose from MDCT is greater
than or equivalent to that of V/PSCAN [47]. The advantage
of V/PSPECT increases after the first trimester.
Follow-up
Follow-up of PE using imaging is essential to:
& Assess the effect of therapy
& Differentiate between new and old PE on suspicion of
PE recurrence
& Investigate physical incapacity after PE
In symptomatic patients treated for PE, the outcome varies,
from total resolution of thrombi within days, to permanent
vascular occlusion. In spite of this, most patients are treated
with heparin/warfarin for 6 months. Some patients have a
tendency to recurrent episodes of PE. Without initial and
follow-up images, it is often impossible to differentiate
between old and new PE. In patients with low resolution of
thrombus and, particularly in those with recurrent emboli, life-
long therapy is indicated. In this group of patients physical
capacity is often reduced. Follow-up imaging may explain
symptoms caused by unresolved PE [59] or by other diseases,
e.g. COPD or heart failure.
Patients treated with thrombolysis for massive PE suffer
the risk of bleeding, but also dangers related to unresolved
PE. Immediate control gives objective information about
the need for repeated thrombolysis.
Symptomatic patients with small emboli are diagnosed by
sensitive methods, particularly V/PSPECT. The natural history
and the value of treatment in this group of patients are not
fully elucidated. Follow-up is indicated to individualize
therapy, as further discussed under Suitability for Research.
V/PSPECT meets the requirements for methods used in
follow-up including:
& Applicability in all patients
& Low radiation dose
& High sensitivity to allow estimation of resolution of
even small emboli and occurrence of new ones
Recommendation
V/PSPECT is ideally suited for use in the follow-up of PE
because small and large emboli are recognized so that
regression or progression of thrombotic disease can be
studied in detail. Furthermore, the low radiation exposure
allows repeated studies. It can be applied in all patients.
Obviously, using the same method for diagnosis and for
follow-up has great advantages. Perfusion-only scintigraphy
may be chosen for control during the initial phase of
treatment.
Suitability for research
Knowledge about the natural history of PE is limited. There
is a need to study alternative strategies for PE therapy, with
respect to therapy duration and choice of drugs in different
categories of patients. It is likely that shorter and less-
dangerous treatment protocols might be preferable in
selected patients. The low incidence of symptomatic PE at
follow-up after negative imaging tests might be explained
by the fact that most emboli are nonocclusive and cause no
harm. The lung is an efficient filter for emboli, which may
be a common and natural phenomenon. It has in most
people a high capacity to resolve thrombi fast, regardless of
initial PE extension. This has been shown by a 44% decrease
in perfusion defects after only 5 days of low molecular
heparin treatment, which in itself has no thrombolytic effect
[60]. Very short treatment, or even no treatment, might be
the preferred strategy in selected patients.
The demands on an imaging technique for research into
PE and its treatment are in principle the same as for clinical
follow-up. However, in research, the motivation to use
nontraumatic procedures associated with the lowest possible
risks is for ethical reasons even stronger.
The issue of small emboli is particularly important. We
still have limited knowledge about the need for treatment.
Only the most sensitive method, i.e. V/PSPECT, can be used
to clarify such problems.
Recommendation
V/PSPECT is recommended for research into the natural
course and treatment of PE.
Diagnostic algorithms
PE, when suspected, must be confirmed or refuted to avoid
the risks of both over and under treatment. This requires
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imaging tests. Only optimal techniques are recommended.
These are MDCT and V/PSPECT with holistic interpretation.
The imaging modality used will depend on availability.
While MDCT is more readily available, it is contraindicated
in a substantial numbers of patients as shown in the
PIOPED II study [10]. At present, V/PSPECT is rarely
available over 24 hours 7 days a week. Accordingly, these
two methods should be available at least in tertiary hospital
centres because both are crucial for adequate algorithms for
the diagnosis of PE. In each centre, the algorithm applied
for the diagnosis of PE must be based upon local circum-
stances, and first and foremost upon the availability of V/
PSPECT and MDCT.
& MDCT is in general more readily available than V/PSPECT
& V/PSPECT carries no risk associated with contrast agent
injection
& V/PSPECT gives a much lower radiation burden
& V/PSPECT yields a lower rate of nondiagnostic reports
& V/PSPECT has higher sensitivity at similar specificity
& V/PSPECT allows better estimation of PE extension
based upon the functional impact of PE
It follows that, when available, V/PSPECT offers consid-
erable advantages over other imaging techniques for the
diagnosis of PE. These advantages include its high
sensitivity and specificity for the diagnosis of PE, its lower
and predictable radiation burden, and its suitability for
follow-up of patients with PE and for research into the
natural history of PE. On the basis of the recent
methodological development of V/PSPECT and documenta-
tion of its performance, it is recommended that this method
is made more generally available. Under ideal circum-
stances either V/PPLANAR or V/PSPECT can be performed
and interpreted within 1 hour of referral [43, 61]. It is
acknowledged that MDCT is widely and readily available
and that it will take some time for V/PSPECT to reach parity
with MDCT. Accordingly, diagnostic algorithms should be
based upon V/PSPECT and MDCT. From centres with no
availability of V/PSPECT, patients may be referred for V/
PSPECT studies elsewhere, when indicated.
The knowledge on V/PSPECT is available. As there are
only a few centres using this technique and particularly its
holistic interpretation, there is a need for systematic
teaching and training. This is a responsibility of the Nuclear
Medicine discipline.
According to good clinical practice, V/PSPECT should be
widely implemented and its performance assessed using
clinical audit.
In the algorithm illustrated in Fig. 3, the entry point is based
on the clinical probability of PE, as illustrated in Fig. 1.
Acute PE suspectedA
PE positiveI
V/PSPECTC
PE negativeKPE positiveFNon-diagnosticE Non-diagnostic J
V/PPLANAR or MDCTH
PE negativeD
PE refuted PE refutedM
Sus
picio
n +
Suspicion-
Further testsLMDCT or PA TREAT
V/PSPECT
available
B V/P
SPECT unavailableG
Fig. 3 Algorithm for diagnostic imaging of patients with clinically
suspected acute PE. A Clinical suspicion derived from Prediction
Models. B V/PSPECT is the procedure of choice; if V/PSPECT is not
immediately available, consider treatment (heparin) depending on
clinical circumstances. C V/PSPECT is interpreted according to the
holistic principle in which clinical pretest probability is a part. D A
normal V/PSPECT is observed in the majority of cases and excludes PE
in almost 100%. E Few cases are non-diagnostic; further diagnostic
procedures are recommended, such as MDCT or in special cases PA. F
V/PSPECT is the most sensitive method; positive findings should lead
to treatment in nearly all cases; research is urgently needed into the
treatment of very low grade of mismatch indicating PE. G V/PPLANAR,
holistically interpreted, or MDCT is recommended when V/PSPECT is
not readily available. H V/PPLANAR is preferred on the basis of its
better negative predictive value, no contraindications and much lower
radiation exposure. I If V/PPLANAR or MDCT is positive treatment is
warranted in most cases; in the context of a low pretest probability, a
positive V/PPLANAR or a MDCT without direct visualization of the
embolism is an indication for further investigation. J When V/
PPLANAR or MDCT is negative, further tests are indicated. K When V/
PPLANAR or MDCT is negative and the clinical suspicion of PE
persists, further tests for PE should be performed. L In this context, V/
PSPECT is the preferred additional test; if not available, MDCT should
be followed by V/PPLANAR or vice versa; PA remains an alternative if
the diagnosis remains unclear. M A normal V/PPLANAR excludes PE;
where the V/PPLANAR is abnormal but negative for PE, or the MDCT
is negative, PE is ruled out in those patients in whom clinical
suspicion of PE is low
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Table 3 Types of evidence
Level Type of evidence
la Obtained from meta-analysis of randomized controlled trials
lb Obtained from at least one randomized controlled trial
IIa Obtained from at least one well-designed controlled study without randomization
IIb Obtained from at least one other type of well-designed quasiexperimental study
III Obtained from well-designed nonexperimental descriptive studies, such as comparative studies, correlation studies and case-control studies
IV Expert opinion
Based on AHCPR, 1992
Table 4 Key to grades of recommendations
Grade Evidence
level
Description
A la, lb Requires at least one randomized controlled trial as part of the body of literature of overall good quality and consistency
addressing the specific recommendation
B IIa, IIb, III Requires availability of well-conducted clinical studies, but no randomized clinical trials on the topic of recommendation
C IV Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates
absence of directly applicable studies of good quality
Based on AHCPR, 1994
Table 5 Key recommendations for the clinical assessment of suspected PE
Recommendation Level Grade
Clinical probability should be used to select patients for imaging studies in suspected PE Ib A
In patients with a low clinical probability of PE and a normal quantitative D-dimer, further imaging tests for PE are
not normally required
IIa B
Patients requiring imaging tests for suspected PE should undergo these investigations within 24 h of referral IV C
In patients with suspected massive PE, the diagnosis should be established with haste allowing appropriate treatment to
commence. In these circumstances echocardiography, MDCT or V/PSCAN imaging may assist with diagnosis depending
on availability
IV C
In patients with suspected pulmonary embolism awaiting confirmatory tests, treatment with heparin should be commenced
without delay unless contraindicated
Ib A
Table 6 Key recommendations for the use of ventilation scintigraphy in PE imaging
Recommendation Level Grade
A ventilation study should be done to support the perfusion scan in all patients with suspected PE, except during the
first trimester of pregnancy
Ib A
81mKr is the radioactive gas of choice, when available, being a true gas and allowing simultaneous acquisition with
the perfusion images
III B
Radiolabelled aerosols with documented particle size and distribution pattern are recommended on the basis of their
widespread availability
III B
99mTc-Technegas is the agent of choice in the presence of obstructive lung disease III B
99mTc-DTPA aerosol is the agent of choice when 99mTc-Technegas is not available III B
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Table 7 Key recommendations for the investigation of regional pulmonary perfusion in PE diagnosis
Recommendation Level Grade
99mTc-MAA is the agent recommended for perfusion scintigraphy IIa B
The minimum number of particles is 60,000, but ideally the number should be about 400,000 III B
In infants/children and in patients with known pulmonary hypertension the number of particles should be
reduced
III B
The vial should be gently shaken before injection and blood withdrawal into the syringe before injection should
be avoided
IV C
Injection should be performed under normal tidal breathing in the supine position IV C
Table 8 Key recommendations for imaging protocols using lung scintigraphy in PE diagnosis
Recommendation Level Grade
For PE imaging a 1-day V/P study should be performed, starting with ventilation, followed by perfusion, aiming
for an activity ratio of 1:4
IIb B
V/PSPECT is preferred to V/PPLANAR when using V/PSCAN for PE diagnosis IIb B
When using planar imaging, a minimum of six views is recommended IIb B
In pregnancy, particularly during the first trimester, a 2-day protocol starting with a perfusion-only scan followed
if necessary by a second day ventilation study
IV C
Table 9 Key recommendations for the interpretation and reporting of V/P scans in PE diagnosis
Recommendation Level Grade
Probabilistic criteria such as that used in the PIOPED studies are flawed and should not be used for the interpretation
of the V/PSCAN
IV C
No PE should be reported if the perfusion scan is normal as defined by the anatomic boundaries of the lungs Ia A
No PE should be reported if perfusion defects are matched or reverse mismatched IIb B
No PE should be reported if perfusion defects do not conform to vascular anatomy, i.e. pulmonary, lobar,
segmental or subsegmental in pattern
IIb B
PE should be reported if there is at least one segmental or two subsegmental perfusion defects IIb B
The lung scan report should include mention of all relevant findings particularly when this may have a bearing
on further patient management
III B
The report of the lung scan with recommendations for further management should be communicated without
delay to the referring clinical team
IV C
V/PSPECT is ideally suited for use in the follow-up of PE because small and large emboli can be assessed for
regression or progression
IV C
V/PSPECT is a useful tool for research about the natural course and treatment of PE IV C
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Key to evidence statements and grades
of recommendations
The definition of types of evidence and the grading of
recommendations used in the guidelines follow those of the
Agency for Healthcare Research and Quality (formerly
Agency for Health Care Policy and Research, AHCPR), as
set out in Tables 3 and 4. The key recommendations
highlighted by the Guideline Development Group are set
out in Tables 5 to 9.
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